A more efficient enzyme-linked immunosorbent assay for measurement of α-synuclein in cerebrospinal fluid

被引：28

作者：

van Geel, Wieneke J. A. ^{[2
]}

Abdo, W. Farid ^{[1
,3
]}

Melis, Rene ^{[4
,5
]}

Williams, Sonja ^{[2
]}

Bloem, Bastlaan R. ^{[1
,3
]}

Verbeek, Marcel M. ^{[1
,2
,3
,4
]}

机构：

[1] Radbound Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands

[2] Radbound Univ Nijmegen, Med Ctr, Lab Pediat & Nephrol, NL-6500 HB Nijmegen, Netherlands

[3] Radbound Univ Nijmegen, Med Ctr, Parkinson Ctr ParC, NL-6500 HB Nijmegen, Netherlands

[4] Radbound Univ Nijmegen, Med Ctr, Alzheimers Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands

[5] Radbound Univ Nijmegen, Med Ctr, Dept Geriatr Med, NL-6500 HB Nijmegen, Netherlands

来源：

JOURNAL OF NEUROSCIENCE METHODS | 2008年 / 168卷 / 01期

关键词：

alpha-synuclein; cerebrospinal fluid; Parkinson's disease; multiple system atrophy; ELISA;

D O I：

10.1016/j.jneumeth.2007.09.021

中图分类号：

Q5 [生物化学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

We describe a modification of a previously described assay for the quantification of alpha-synuclein in naive cerebrospinal fluid, which allows for a more efficient quantification of a-synuclein. Detection limit of the assay is 3.8 ng/ml and the assay is linear until 300 ng/ml. Inter-assay and intra-assay coefficients of variation are below 15% in a wide range of concentrations. Mean recovery of the assay is 94%. The 95% upper limit of the reference range (p95) in a group of neurological controls above the age of 45 years is 62 ng/ml. This assay can be routinely applied for quantification of a-synuclein in cerebrospinal fluid, but not in serum, and this may serve as a possible biomarker for alpha-synucleinopathies such as Parkinson's disease and multiple system atrophy. (c) 2007 Elsevier B.V. All rights reserved.

引用

页码：182 / 185

页数：4

共 17 条

[1]

CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia [J].

Abdo, W. F. ;

van de Warrenburg, B. P. C. ;

Munneke, M. ;

van Geel, W. J. A. ;

Bloem, B. R. ;

Kremer, H. P. H. ;

Verbeek, M. M. .

NEUROLOGY, 2006, 67 (03) :474-479

[2]

CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease [J].

Abdo, W. Farid ;

Bloem, Bastiaan R. ;

Van Geel, Wieneke J. ;

Esselink, Rianne A. J. ;

Verbeek, Marcel M. .

NEUROBIOLOGY OF AGING, 2007, 28 (05) :742-747

[3]

Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease [J].

Abdo, WF ;

de Jong, D ;

Hendriks, JCM ;

Horstink, MWIM ;

Kremer, BPH ;

Bloem, BR ;

Verbeek, MM .

MOVEMENT DISORDERS, 2004, 19 (05) :571-579

[4]

ALAGNAF OM, 2006, FASEB J, V20, P419

[5]

α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers [J].

Beyer, Katrin .

ACTA NEUROPATHOLOGICA, 2006, 112 (03) :237-251

[6]

CSF markers for incipient Alzheimer's disease [J].

Blennow, K ;

Hampel, H .

LANCET NEUROLOGY, 2003, 2 (10) :605-613

[7]

Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects [J].

Borghi, R ;

Marchese, R ;

Negro, A ;

Marinelli, L ;

Forloni, G ;

Zaccheo, D ;

Abbruzzese, G ;

Tabaton, M .

NEUROSCIENCE LETTERS, 2000, 287 (01) :65-67

[8]

The native form of α-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls [J].

Jakowec, MW ;

Petzinger, GM ;

Sastry, S ;

Donaldson, DM ;

McCormack, A ;

Langston, JW .

NEUROSCIENCE LETTERS, 1998, 253 (01) :13-16

[9]

Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form [J].

Lee, HJ ;

Choi, C ;

Lee, SJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (01) :671-678

[10]

Intravesicular localization and exocytosis of α-synuclein and its aggregates [J].

Lee, HJ ;

Patel, S ;

Lee, SJ .

JOURNAL OF NEUROSCIENCE, 2005, 25 (25) :6016-6024

← 1 2 →